{"url_path":"/sec/apvo/8-k/2026-06-30/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1671584/0001193125-26-290473-index.html","accession_number":"0001193125-26-290473","cik":"0001671584","ticker":"APVO","issuer_name":"Aptevo Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1671584/0001193125-26-290473-index.html","primary_entity_key":"0001671584","primary_entity_name":"Aptevo Therapeutics Inc."},"word_count":109,"has_tables":true,"body_markdown":"Item 7.01. Regulation FD Disclosure.\n\nOn June 30, 2026, Aptevo Therapeutics Inc. issued a press release announcing its entry into the Agreement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing."}